Lavipharm share capital increase

Papapolitis & Papapolitis advised Ambrosia Capital as Lead Underwriter in relation to the €58m pre-emptive share capital increase of Lavipharm S.A., a leading pharmaceutical company with global presence, and to the public offer in Greece of newly issued shares listed on Athex. P&P advised the Lead Underwriter on all aspects of the transaction including customary due diligence of the issuer, review and drafting of the offering prospectus for approval by the Hellenic Capital Market Commission as well as general aspects of corporate and capital market rules and regulations in relation to the marketing and public offer of the new shares and the private placement of rump shares.